SG2014008346A - Combinations of hepatitis c virus inhibitors - Google Patents
Combinations of hepatitis c virus inhibitorsInfo
- Publication number
- SG2014008346A SG2014008346A SG2014008346A SG2014008346A SG2014008346A SG 2014008346 A SG2014008346 A SG 2014008346A SG 2014008346 A SG2014008346 A SG 2014008346A SG 2014008346 A SG2014008346 A SG 2014008346A SG 2014008346 A SG2014008346 A SG 2014008346A
- Authority
- SG
- Singapore
- Prior art keywords
- hepatitis
- combinations
- virus inhibitors
- virus
- inhibitors
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37139910P | 2010-08-06 | 2010-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG2014008346A true SG2014008346A (en) | 2014-05-29 |
Family
ID=45559795
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2014008346A SG2014008346A (en) | 2010-08-06 | 2011-08-02 | Combinations of hepatitis c virus inhibitors |
| SG2013005905A SG187193A1 (en) | 2010-08-06 | 2011-08-02 | Combinations of hepatitis c virus inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013005905A SG187193A1 (en) | 2010-08-06 | 2011-08-02 | Combinations of hepatitis c virus inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20120196794A1 (enExample) |
| EP (1) | EP2600835B1 (enExample) |
| JP (2) | JP6196154B2 (enExample) |
| KR (1) | KR101846596B1 (enExample) |
| CN (2) | CN105148275A (enExample) |
| AU (1) | AU2011285890B2 (enExample) |
| BR (1) | BR112013002922A2 (enExample) |
| CA (1) | CA2807589C (enExample) |
| EA (1) | EA022303B1 (enExample) |
| ES (1) | ES2685174T3 (enExample) |
| IL (1) | IL224369B (enExample) |
| MX (1) | MX2013001170A (enExample) |
| SG (2) | SG2014008346A (enExample) |
| WO (1) | WO2012018829A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20120196794A1 (en) * | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
| BR112013004520A2 (pt) | 2010-08-26 | 2016-06-07 | Univ Emory | inibidores potentes e seletivos do virus da hepatite c |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9243025B2 (en) * | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PT107894A (pt) | 2011-10-21 | 2014-10-31 | Abbvie Inc | Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão. |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX360452B (es) | 2012-10-19 | 2018-11-01 | Bristol Myers Squibb Co | Inhibidores del virus de la hepatitis c. |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2015009744A1 (en) | 2013-07-17 | 2015-01-22 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ES2435799T3 (es) * | 2008-10-09 | 2013-12-23 | Anadys Pharmaceuticals, Inc. | Un método de inhibición del virus de la hepatitis C mediante combinación de una 5,6-dihidro-1H-piridin-2-ona y de uno o más compuestos antivirales adicionales |
| US8415374B2 (en) * | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| US20120196794A1 (en) * | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
-
2011
- 2011-08-01 US US13/195,317 patent/US20120196794A1/en not_active Abandoned
- 2011-08-02 ES ES11815206.5T patent/ES2685174T3/es active Active
- 2011-08-02 WO PCT/US2011/046285 patent/WO2012018829A1/en not_active Ceased
- 2011-08-02 EA EA201390155A patent/EA022303B1/ru not_active IP Right Cessation
- 2011-08-02 MX MX2013001170A patent/MX2013001170A/es unknown
- 2011-08-02 BR BR112013002922A patent/BR112013002922A2/pt not_active Application Discontinuation
- 2011-08-02 CA CA2807589A patent/CA2807589C/en not_active Expired - Fee Related
- 2011-08-02 SG SG2014008346A patent/SG2014008346A/en unknown
- 2011-08-02 EP EP11815206.5A patent/EP2600835B1/en not_active Not-in-force
- 2011-08-02 CN CN201510608270.5A patent/CN105148275A/zh active Pending
- 2011-08-02 KR KR1020137005628A patent/KR101846596B1/ko not_active Expired - Fee Related
- 2011-08-02 SG SG2013005905A patent/SG187193A1/en unknown
- 2011-08-02 CN CN201180048188.1A patent/CN103153280B/zh not_active Expired - Fee Related
- 2011-08-02 AU AU2011285890A patent/AU2011285890B2/en not_active Ceased
- 2011-08-02 JP JP2013523278A patent/JP6196154B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-23 IL IL224369A patent/IL224369B/en not_active IP Right Cessation
-
2014
- 2014-04-28 US US14/263,101 patent/US20140235617A1/en not_active Abandoned
-
2015
- 2015-07-31 US US14/814,891 patent/US20150335655A1/en not_active Abandoned
-
2016
- 2016-03-31 JP JP2016072377A patent/JP2016155844A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EA022303B1 (ru) | 2015-12-30 |
| AU2011285890B2 (en) | 2014-12-18 |
| EA201390155A1 (ru) | 2013-05-30 |
| CN105148275A (zh) | 2015-12-16 |
| SG187193A1 (en) | 2013-03-28 |
| KR20140002611A (ko) | 2014-01-08 |
| US20120196794A1 (en) | 2012-08-02 |
| AU2011285890A1 (en) | 2013-03-21 |
| CA2807589C (en) | 2016-08-30 |
| JP2016155844A (ja) | 2016-09-01 |
| US20150335655A1 (en) | 2015-11-26 |
| ES2685174T3 (es) | 2018-10-05 |
| CA2807589A1 (en) | 2012-02-09 |
| EP2600835A4 (en) | 2013-11-20 |
| JP2013535487A (ja) | 2013-09-12 |
| US20140235617A1 (en) | 2014-08-21 |
| KR101846596B1 (ko) | 2018-04-06 |
| BR112013002922A2 (pt) | 2016-06-07 |
| CN103153280B (zh) | 2015-09-09 |
| JP6196154B2 (ja) | 2017-09-13 |
| CN103153280A (zh) | 2013-06-12 |
| IL224369B (en) | 2019-08-29 |
| EP2600835A1 (en) | 2013-06-12 |
| WO2012018829A1 (en) | 2012-02-09 |
| EP2600835B1 (en) | 2018-05-30 |
| MX2013001170A (es) | 2013-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269662A (en) | Hepatitis C virus inhibitors | |
| IL224369B (en) | Combinations of inhibitors for hepatitis c virus | |
| ZA201303752B (en) | Inhibitors of hepatitis c virus | |
| IL221033A0 (en) | Hepatitis c virus inhibitors | |
| EP2575819A4 (en) | INHIBITORS OF HEPATITIS C VIRUS | |
| IL224298A (en) | Hepatitis virus inhibitors c | |
| AP3576A (en) | Inhibitors of flaviviridae viruses | |
| EP2603080A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| HRP20130671T1 (en) | Hepatitis C virus inhibitors | |
| IL214775A0 (en) | Hepatitis c virus inhibitors | |
| EP2475256A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| EP2512480A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| AP2012006413A0 (en) | Inhibitors of flaviviridae viruses | |
| ZA201306720B (en) | Hepatitis c virus inhibitors | |
| IL229270B (en) | Hepatitis c virus inhibitors | |
| EP2768517A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| ZA201309356B (en) | Hepatitis c virus inhibitors | |
| EP2651906A4 (en) | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | |
| HK1178380A (en) | Hepatitis c virus inhibitors |